Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719
0719 Stock Chart & Stats
HK$6.67
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$6.67
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$5.11 - HK$9.46
Previous CloseN/A
Volume2.84M
Average Volume (3M)1.49M
Market Cap
HK$9.64B
Enterprise ValueHK$8.00B
Total Cash (Recent Filing)HK$1.40B
Total Debt (Recent Filing)HK$1.31B
Price to Earnings (P/E)14.5
Beta0.63
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.47%
Share Statistics
EPS (TTM)0.28
Shares Outstanding195,000,000
10 Day Avg. Volume1,000,110
30 Day Avg. Volume1,490,646
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.48
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.94
Revenue Forecast (FY)HK$9.35B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line expansion across 2020–2024 and continued TTM growth indicates durable product demand and commercial reach. This steady revenue base supports longer-term planning, capacity utilization, and incremental margin recovery potential as fixed costs spread over higher sales.
Rebound In Free Cash FlowA pronounced recovery in free cash flow improves the firm's ability to fund operations, capex and shareholder returns without relying on external financing. Strengthening FCF enhances financial resilience and provides flexibility to invest in product pipelines or distribution over the medium term.
Manageable Leverage And Expanded EquityModerate debt ratios and asset/equity expansion signal a resilient balance sheet with room to absorb shocks and fund strategic initiatives. Controlled leverage supports credit flexibility and lowers refinancing risk, enabling sustained operations and investment through business cycles.
Bears Say
Significant Margin CompressionA sharp, multi-year decline in gross and net margins erodes inherent profitability and reduces the company's ability to convert revenue into durable earnings. Structural margin pressure can limit reinvestment, R&D spending and dividend sustainability absent sustained cost or pricing remediation.
Declining Return On EquityROE falling by roughly half signals weakening capital efficiency and lower returns on shareholder funds. Persistently lower ROE suggests the business is generating less profit per unit of equity, constraining long-term investor returns and potentially reflecting competitive or margin pressures.
Inconsistent Cash ConversionVolatile cash conversion and FCF covering only ~62% of net income indicate earnings do not reliably convert to cash. This inconsistency raises execution risk for funding capex, servicing obligations, or maintaining dividends during downturns and may force reliance on financing.
Shandong Xinhua Pharmaceutical Company Limited Class H News
0719 FAQ
What was Shandong Xinhua Pharmaceutical Company Limited Class H’s price range in the past 12 months?
Shandong Xinhua Pharmaceutical Company Limited Class H lowest stock price was HK$5.11 and its highest was HK$9.46 in the past 12 months.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap?
Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap is HK$9.64B.
When is Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date?
Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date is Apr 29, 2026 which is in 23 days.
How were Shandong Xinhua Pharmaceutical Company Limited Class H’s earnings last quarter?
Shandong Xinhua Pharmaceutical Company Limited Class H released its earnings results on Mar 27, 2026. The company reported HK$0.285 earnings per share for the quarter, the consensus estimate of HK$0.285 by HK$0.
Is Shandong Xinhua Pharmaceutical Company Limited Class H overvalued?
According to Wall Street analysts Shandong Xinhua Pharmaceutical Company Limited Class H’s price is currently Overvalued.
Does Shandong Xinhua Pharmaceutical Company Limited Class H pay dividends?
Shandong Xinhua Pharmaceutical Company Limited Class H pays a Annually dividend of HK$0.273 which represents an annual dividend yield of 4.47%. See more information on Shandong Xinhua Pharmaceutical Company Limited Class H dividends here
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate?
Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shandong Xinhua Pharmaceutical Company Limited Class H have?
Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding.
What happened to Shandong Xinhua Pharmaceutical Company Limited Class H’s price movement after its last earnings report?
Shandong Xinhua Pharmaceutical Company Limited Class H reported an EPS of HK$0.285 in its last earnings report, expectations of HK$0.285. Following the earnings report the stock price went up 1.212%.
Which hedge fund is a major shareholder of Shandong Xinhua Pharmaceutical Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0719
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Xinhua Pharmaceutical Company Limited Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.34%
12-Months-Change
Fundamentals
Return on Equity
7.49%
Trailing 12-Months
Asset Growth
1.74%
Trailing 12-Months
Company Description
Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Earnings & Revenues
Technical Analysis
SSY Group
―
Sihuan Pharmaceutical Holdings Group
―
Consun Pharmaceutical Group Ltd.
―
―
CanSino Biologics, Inc. Class H
―
Options Prices
Currently, No data available
---